Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.